IE
EIGR

Israel Englander’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Israel Englander’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-279
Closed -$2.38M – 3959
2015
Q1 		$2.38M Buy
+279
New +$2.44M ﹤0.01% 1846

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
AWP
Accretive Wealth Partners Parsippany, New Jersey $412M AUM 15.82% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.41B AUM 39.41% 1-Year Est. Return

Israel Englander's EIGR Position: Q1 2024 in Review

Israel Englander sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2024, closing a stake of 2,705 shares — an estimated $18.2K sold.

Israel Englander first reported a position in EIGR in Q2 2014 and held it in 20 quarters. The position peaked at $16.8M in Q1 2015. 24 funds tracked by Wall St. Rank hold EIGR as of Q1 2024.

  • Israel Englander reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
  • Israel Englander sold 2,705 Eiger BioPharmaceuticals, Inc. shares in Q1 2024, an estimated $18.2K.
  • Israel Englander first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2014 and held it in 20 quarters.
  • Israel Englander's Eiger BioPharmaceuticals, Inc. position peaked at $16.8M in Q1 2015.
  • 24 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2024.

Based on Millennium Management's 13F filing for Q1 2024, filed 15 May 2024.